Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03900468 · ClinicalTrials.gov registry record · NA

Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)

A NA study of Epilepsy, sponsored by MedtronicNeuro.

Active
Registry status
NA
Development phase
140
Enrollment target
13
Study locations

NCT03900468: Active NA study of Epilepsy, sponsored by MedtronicNeuro.

NCT03900468 is a NA study of Epilepsy that is active but no longer recruiting, run by MedtronicNeuro. The registered enrollment target is 140 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (85% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03900468, a NA study of Epilepsy, is active but no longer recruiting, sponsored by MedtronicNeuro.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
140 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.

Primary Outcome

The percentage of total seizure frequency reduction will be assessed using the participant seizure diaries to demonstrate DBS therapy effectiveness

Conditions Studied

Interventions

  • DEVICE Activa™ PC and Percept™ PC Neurostimulation Systems

Study Locations (13)

California

  • University of California Los Angeles (UCLA) - Los Angeles
  • University of California San Francisco UCSF Medical Center - San Francisco
  • Stanford Hospital & Clinics - Stanford

Ohio

  • Cleveland Clinic - Cleveland
  • The Ohio State University - Columbus

Georgia

  • Emory University Hospital - Atlanta

Illinois

  • Rush University Medical Center - Chicago

Indiana

  • Indiana University Health Neuroscience Center - Indianapolis

Kansas

  • University of Kansas Medical Center - Kansas City

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • Mayo Clinic (Rochester MN) - Rochester

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2020-03-05
Est. Completion 2026-03-27
Phase NA
MedtronicNeuro

51 total trials

What the registry record for NCT03900468 still lists

NCT03900468 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Activa™ PC and Percept™ PC Neurostimulation Systems is the first listed.

NCT03900468 lists 13 locations in 10 states (California, Ohio, Georgia).

Frequently Asked Questions

What is clinical trial NCT03900468 about?

NCT03900468 is a clinical study titled "Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)". The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.

What is the current status of trial NCT03900468?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2020-03-05. Estimated completion is 2026-03-27.

What conditions does trial NCT03900468 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT03900468?

The interventions under investigation include: Activa™ PC and Percept™ PC Neurostimulation Systems (DEVICE).

Who is sponsoring clinical trial NCT03900468?

This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03900468 being conducted?

This trial has 13 study locations across California, Georgia, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03900468's enrollment target sits among peer trials

140 43rd of 160 higher than 118 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03900468, the US trial registry maintained by the National Library of Medicine. NCT03900468 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.